Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Solid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Malignant Neoplasmas 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Leukemia 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1

Interventions

Cisplatin 17pembrolizumab 12Radiotherapy 11Nivolumab 7Cetuximab 6Paclitaxel 5fludarabine 4aldesleukin 4Radiation 4Interleukin-2 4Docetaxel 4Cyclophosphamide 4olaparib 3fludarabine phosphate 3Carboplatin 3talimogene laherparepvec 2atezolizumab 2Taxes 2Sorafenib 2Fluorouracil 2Erlotinib Hydrochloride 2Drug Therapy 2Capecitabine 2Bortezomib 2130-nm albumin-bound paclitaxel 2vandetanib 1tozuleristide 1tilsotolimod 1testosterone enanthate 1temoporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Squamous Cell × ON 01910 × Clear all
NCT02107235 2017-06-23

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

Traws Pharma, Inc.

Phase 1 Completed
2 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡